ENO can be modulated by m6A modifiers, including METTL3, KIAA1429, WTAP, YTHDF2 and ALKBH5, mediating the cell glycolysis process in lung adenocarcinoma, breast cancer and ovarian cancer [186–189]. Here, ALKBH5 is linked to breast carcinoma.